Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 338.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 3.00 (0.896%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 338.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS: Hutchmed revenue surges, Craven House's loss widens

Wed, 28th Feb 2024 17:31

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Hutchmed (China) Ltd - Hong Kong-based developer of treatments for cancer and immunological diseases - Says it swings to net income of USD100.8 million for 2023, from a USD360.8 million net loss in 2022. Revenue rises 97% to USD838.0 million from USD426.4 million, with Oncology/Immunology consolidated revenue more than tripling to high end of guidance, at USD528.6 million. Includes USD280 million of an upfront payment from deal with Takeda Pharmaceutical Co Ltd. Cash balance at December 31 is USD886.3 million, up from USD631.0 million one year prior. Company does not recommend a final dividend, unchanged from 2022. Guides for USD300 million to USD400 million in Oncology/Immunology consolidated revenue in 2024.

----------

Cykel AI PLC - London-based artificial technologies firm, founded in August 2023 - Posts operating loss and pretax loss of GBP1.4 million for the period from August 22 to November 30. Cash balance at November 30 is GBP1.6 million. Says management team continues to develop and refine its task operating system, pending the expected reverse takeover by London-based special purpose acquisition company Mustang Energy PLC agreed in January.

----------

Harmony Energy Income Trust PLC - Great Britain-focused investor in commercial-scale battery energy storage systems - Net asset value at October 31 is 115.40 pence per share, down from 120.55p one year previously. Reports adjusted NAV total return of positive 1.2% for the year to October 31, following a positive 23.4% return the year before. Pretax profit falls to GBP3.1 million from GBP48.4 million. Company increases total dividend for year to 8p per share from 2p, and says it is working hard to find solutions to its current challenges, including the "deteriorated" Great British battery energy storage systems or BESS market. Acknowledges however that due to "unexpectedly low" income its dividends were paid using VAT rebates, "which the board recognises is not what shareholders expect over the long term".

----------

Craven House Capital PLC - London-based investment fund with minority shareholding in four Swedish-managed eCommerce and pharmaceutical businesses - Pretax loss for six months to November 30 is USD114,000, widening from USD72,000 the prior year. Assets at period end total USD1.16 billion, down from USD6.43 billion one year prior. Loss per share widens to 2.95 US cents from 1.86 cents. Says investees remain at 'pre-revenue' stage of business development.

----------

Malin Corp PLC - Dublin-based investor in life sciences companies - Says cash at December 31 is EUR29.3 million, compared to USD173.9 million at the same time one year prior. This has grown to EUR34.5 million at February 26 due to receipt of a contingent milestone payment from a disposal to Sanofi SA in 2021. Estimated intrinsic equity value was EUR6.56 per share at December 31 and EUR7.91 at February 26. Company says it returns EUR140.7 million of capital to shareholders throughout 2023 with a tender offer and on-market buybacks. Company also says Executive Chair Liam Daniel's role will revert to non-executive chair from Thursday.

----------

AIQ Ltd - company focused on acquiring and developing e-commerce sector businesses - Revenue for the year to October 31 falls to GBP207,209 from GBP496,296 annually. Pretax loss widens to GBP503,198 from GBP336,731. Says these results reflect challenging environment for non-fungible tokens and other blockchain technology-based products. Cash balance at October 31 is GBP135,445, down from GBP636,459 one year prior. Company says it continues to closely monitor its cash position and "is keeping all its strategic options open should the markets not turn favourable in the near-term".

----------

Renewables Infrastructure Group Ltd - investor in wind, solar and battery storage projects in Europe, advised by InfraRed Capital Partners Ltd - NAV per share at December 31 is 127.7p, down from 134.6p one year prior. Says reduction was driven by lower power price forwards and higher valuation discount rates. Says portfolio revenue for 2023 was GBP793 million, down from GBP838 million in 2022. Portfolio earnings before interest, tax, depreciation and amortisation falls to GBP610 million from GBP677 million. Dividend for 2023 totals 7.18p per share, and company is targeting a payout of 7.47p per share for 2024. Adds that the macroeconomic environment looks more "benign" this year.

----------

By Emma Curzon, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
29 Aug 2023 09:30

IN BRIEF: China grants Hutchmed's savolitinib breakthrough therapy tag

Hutchmed (China) Ltd - Hong Kong-based developer of treatments for cancer and immunological diseases - Wins 'breakthrough therapy designation' in China for its gastric cancer treatment, savolitinib. The BTD is granted by the National Medical Products Administration. It is for the treatment of locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma patients with mesenchymal epithelial transition factor amplification who have failed at least two lines of standard therapies. Hutchmed notes that MET-driven gastric cancer has a poor prognosis, and China grants a BTD to new drugs that treat life-threatening diseases for which there are no effective treatment options.

Read more
21 Aug 2023 08:46

Hutchmed China hails trial on sovleplenib meeting primary endpoint

(Alliance News) - Hutchmed (China) Ltd on Monday said a phase 3 trial evaluating the investigational use of sovleplenib met its primary endpoint.

Read more
21 Aug 2023 08:24

Hutchmed meets all endpoints in platelet disorder treatment trial

(Sharecast News) - Hutchmed China reported a breakthrough from its recent phase three trial in sovleplenib on Monday, reporting that it met its primary endpoint and all secondary endpoints for treating adult patients with primary immune thrombocytopenia - a platelet disorder - (ITP) in China.

Read more
31 Jul 2023 12:47

Hutchmed swings to profit after "sharpening goals and priorities"

(Alliance News) - Hutchmed (China) Ltd on Monday reported sharp first-half revenue growth, as a strategy change to boost its fortunes outside of China saw early fruit.

Read more
24 Jul 2023 15:46

UK earnings, trading statements calendar - next 7 days

Tuesday 25 July 
City of London Investment Group PLCTrading Statement
Compass Group PLCTrading Statement
Croda International PLCHalf Year Results
Games Workshop Group PLCFull Year Results
Greencore Group PLCTrading Statement
Hummingbird Resources PLCTrading Statement
MITIE Group PLCTrading Statement
Paragon Banking Group PLCTrading Statement
Reach PLCHalf Year Results
Smart Metering Systems PLCTrading Statement
Tristel PLCTrading Statement
Tyman PLCHalf Year Results
Unilever PLCHalf Year Results
Unite Group PLCHalf Year Results
Wednesday 26 July 
Aptitude Software Group PLCHalf Year Results
Breedon Group PLCHalf Year Results
Conduit Holdings LtdHalf Year Results
Ecora Resources PLCTrading Statement
Fresnillo PLCTrading Statement
FRP Advisory Group PLCFull Year Results
Gresham Technologies PLCHalf Year Results
Lloyds Banking Group PLCHalf Year Results
Marston's PLCTrading Statement
Nichols PLCHalf Year Results
Primary Health Properties PLCHalf Year Results
Rathbones Group PLCHalf Year Results
Revolution Bars Group PLCTrading Statement
Rio Tinto PLCHalf Year Results
Science Group PLCHalf Year Results
Van Elle Holdings PLCFull Year Results
Thursday 27 July 
Allianz Technology Trust PLCHalf Year Results
Antofagasta PLCHalf Year Results
Capital & Regional PLCHalf Year Results
Card Factory PLCTrading Statement
Checkit PLCTrading Statement
Drax Group PLCHalf Year Results
Deliveroo PLCHalf Year Results
Derwent London PLCHalf Year Results
Entain PLCHalf Year Results
Greencoat UK Wind PLCHalf Year Results
Global Connectivity PLCHalf Year Results
Hostelworld Group PLCHalf Year Results
HydrogenOne Capital Growth PLCTrading Statement
Lancashire Holdings LtdHalf Year Results
Mitchells & Butlers PLCTrading Statement
OSB Group PLCHalf Year Results
Persimmon PLCHalf Year Results
Petrofac LtdHalf Year Results
Redcentric PLCFull Year Results
S&U PLCTrading Statement
Savills PLCHalf Year Results
Secure Trust Bank PLCHalf Year Results
Spirax-Sarco Engineering PLCHalf Year Results
Videndum PLCHalf Year Results
Wheaton Precious Metals CorpHalf Year Results
Friday 28 July 
AIB Group PLCHalf Year Results
GCP Infrastructure Investments LtdTrading Statement
International Consolidated Airlines Group SAHalf Year Results
Intertek Group PLCHalf Year Results
Jardine Matheson Holdings LtdHalf Year Results
NatWest Group PLCHalf Year Results
PayPoint PLCFull Year Results
PayPoint PLCTrading Statement
Standard Chartered PLCHalf Year Results
YouGov PLCTrading Statement
Monday 31 July 
Hutchmed (China) LtdHalf Year Results
Pearson PLCHalf Year Results
Pod Point Group Holdings PLCHalf Year Results
Quartix Technologies PLCHalf Year Results
Spectris PLCHalf Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
20 Jul 2023 14:14

IN BRIEF: Hutchmed progresses fruquintinib designation and testing

Hutchmed (China) Ltd - Hong Kong-based developer of treatments for cancer and immunological diseases - Granted breakthrough therapy designation, by the Center for Drug Evaluation of China's National Medical Products Administration, for oral inhibitor fruquintinib combined with PD-1 antibody sintilimab. BTD is for treatment of patients with previously treated advanced endometrial cancer.

Read more
10 Jul 2023 12:58

Hutchmed launches new phase one study in China

(Sharecast News) - Biopharmaceutical company Hutchmed China announced the launch of a phase one study in China for HMPL-415 on Monday - an investigational selective allosteric inhibitor that targeted Src homology-2 domain-containing protein tyrosine phosphatase-2 (SHP2).

Read more
10 Jul 2023 08:53

IN BRIEF: Hutchmed starts study for tumour treatment in China

Hutchmed (China) Ltd - Hong Kong-based cancer and immunological diseases' treatment developer - Starts phase one study in China of its SHP2 inhibitor HMPL-415 for the treatment of advanced malignant solid tumours. First patient received their first dose on Thursday last week. Hutchmed expects up to 80 patients to take part in the study. SHP2 is a non-receptor protein tyrosine phosphatase which controls cell growth and cell migration.

Read more
16 Jun 2023 08:51

Hutchmed, Takeda Fresco-2 study published in The Lancet

(Alliance News) - Hutchmed (China) Ltd on Friday said phase three results for its Fresco-2 study evaluating fruquintinib in patients with previously treated metastatic colorectal cancer, conducted alongside Takeda Pharmaceutical Co Ltd, were published in peer-reviewed journal, The Lancet.

Read more
16 Jun 2023 08:44

Hutchmed China's colorectal cancer study to be published

(Sharecast News) - Hutchmed China, alongside its partner Takeda, announced the publication of the phase three 'FRESCO-2' study results evaluating the use of fruquintinib in patients with previously-treated metastatic colorectal cancer (CRC) on Friday, in the Lancet medical journal.

Read more
15 Jun 2023 16:51

IN BRIEF: Hutchmed and Takeda get Europe marketing backing for drug

Hutchmed (China) Ltd - Hong Kong-based cancer and immunological diseases treatment developer - Says marketing authorisation application for fruquintinib, made alongside Tokyo-based Takeda Pharmaceutical Co Ltd, has been validated and caccepted by the European Medicines Agency. Fruquintinib is an inhibitor of vascular endothelial growth factor receptors used to treat cancers.

Read more
26 May 2023 13:13

US FDA gives priority to Hutchmed's colorectal cancer treatment

(Sharecast News) - Hutchmed China, in collaboration with Takeda, announced on Friday that the US Food and Drug Administration (FDA) has granted priority review for the New Drug Application (NDA) of fruquintinib.

Read more
26 May 2023 08:56

Hutchmed China celebrates FDA review, teases new data at ASCO meeting

(Alliance News) - Hutchmed China Ltd on Friday celebrated a priority review granted by the US FDA for its cancer drug fruquintinib, and promised to present new data for this and two other therapies at the American Society of Clinical Oncology next month.

Read more
5 May 2023 15:57

UK shareholder meetings calendar - next 7 days

Monday 8 May 
no events scheduled 
Tuesday 9 May 
Caledonia Mining Corp PLCAGM
Direct Line Insurance Group PLCAGM
Foxtons Group PLCAGM
Hostelworld Group PLCAGM
IWG PLCAGM
Just Group PLCAGM
Midwich Group PLCAGM
Osirium Technologies PLCAGM
Windward LtdAGM
Wednesday 10 May 
abrdn PLCAGM
Antofagasta PLCAGM
Cenkos Securities PLCAGM
Ecora Resources PLCAGM
H&T Group PLCAGM
Harbour Energy PLCAGM
Jupiter Fund Management PLCAGM
Literacy Capital PLCAGM
Luceco PLCAGM
Marshalls PLCAGM
National Express Group PLCAGM
Renewables Infrastructure Group LtdAGM
Rentokil Initial PLCAGM
Seplat Energy PLCAGM
Spirax-Sarco Engineering PLCAGM
TClarke PLCAGM
Thursday 11 May 
88 Energy LtdAGM
Cairn Homes PLCAGM
Capita PLCAGM
Clarkson PLCAGM
Costain Group PLCAGM
Eleco PLCAGM
Eurocell PLCAGM
FBD Holdings PLCAGM
Genedrive PLCGM re Equity Prepayment Facility
Genel Energy PLCAGM
Gresham House PLCAGM
Gym Group PLCAGM
Hiscox LtdAGM
Irish Continental Group PLCAGM
John Wood Group PLCAGM
MyHealthChecked PLCAGM
OSB Group PLCAGM
Poolbeg Pharma PLCAGM
Rolls-Royce Holdings PLCAGM
Serinus Energy PLCAGM
Uniphar PLCAGM
Videndum PLCAGM
WAG Payment Solutions PLCAGM
Friday 12 May 
Balfour Beatty PLCAGM
Derwent London PLCAGM
Goodbody Health LtdAGM
GreenRoc Mining PLCAGM
Hutchmed (China) LtdAGM
Itim Group PLCAGM
Itsarm PLCGM re delisting from AIM
Wheaton Precious Metals CorpAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved. 

Read more
18 Apr 2023 12:30

Hutchmed's gastric cancer treatment accepted for review in China

(Sharecast News) - Hutchmed China announced on Tuesday that its new drug application (NDA) for fruquintinib, in combination with paclitaxel has been accepted for review by the National Medical Products Administration (NMPA) in China.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.